| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PMIC.200300598 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpmic.200300598 |
| https://onlinelibrary.wiley.com/doi/full/10.1002/pmic.200300598 | ||
| P698 | PubMed publication ID | 14595813 |
| P5875 | ResearchGate publication ID | 9027784 |
| P50 | author | Lance A. Liotta | Q74243861 |
| P2093 | author name string | Robert L. Grubb | |
| Michael Emmert-Buck | |||
| Rodrigo Chuaqui | |||
| John Gillespie | |||
| W. Marston Linehan | |||
| Emanuel F. Petricoin | |||
| John L. Phillips | |||
| Alfredo Valasco | |||
| Cloud P. Paweletz | |||
| Valerie S. Calvert | |||
| Julia D. Wulkuhle | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Laser capture microdissection | Q28293867 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front | Q30989699 | ||
| Anticancer drug targets: growth factors and growth factor signaling | Q33808352 | ||
| Growth factors and their receptors: new targets for prostate cancer therapy | Q34335662 | ||
| ZD1839 (Iressa): for more than just non-small cell lung cancer | Q34803471 | ||
| Clinical proteomics: translating benchside promise into bedside reality | Q34810370 | ||
| What's new in the treatment of advanced prostate cancer? | Q35037711 | ||
| Cancer statistics, 2003. | Q43729872 | ||
| Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha | Q44353846 | ||
| Rationale for earlier and less frequent prostate cancer screening | Q77182000 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 2142-2146 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Proteomics | Q15614164 |
| P1476 | title | Signal pathway profiling of prostate cancer using reverse phase protein arrays | |
| P478 | volume | 3 |
| Q45052926 | A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation |
| Q93112495 | A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia |
| Q33764388 | A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. |
| Q37711623 | Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer |
| Q57952030 | Antibody and Reverse Capture Protein Microarrays for Clinical Proteomics |
| Q36020258 | Antibody arrays in cancer research |
| Q25257533 | Application of protein lysate microarrays to molecular marker verification and quantification |
| Q37790704 | Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy |
| Q35170387 | Applications of protein microarrays for biomarker discovery |
| Q38255299 | Array-based proteomic approaches to study signal transduction pathways: prospects, merits and challenges |
| Q37994133 | Cancer proteomics |
| Q36960733 | Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective |
| Q33764472 | Combining laser capture microdissection and proteomics: Methodologies and clinical applications |
| Q34336095 | Common Protein Biomarkers Assessed by Reverse Phase Protein Arrays Show Considerable Intratumoral Heterogeneity in Breast Cancer Tissues |
| Q94101631 | Current Awareness on Comparative and Functional Genomics |
| Q28744610 | Discovery of new molecular subtypes in oesophageal adenocarcinoma |
| Q38821536 | Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. |
| Q36396456 | Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells |
| Q34184598 | Functional proteomic profiling of AML predicts response and survival |
| Q33898189 | Future of personalized medicine in oncology: a systems biology approach |
| Q42784850 | Guided protein extraction from formalin‐fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains |
| Q35934672 | High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases |
| Q37727189 | Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue. |
| Q50101328 | Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors |
| Q36766852 | How to comprehensively analyse proteins and how this influences nutritional research |
| Q36973770 | ImmunoCell-Array: a novel technology for pathway discovery and cell profiling |
| Q44186745 | Impact of Blocking and Detection Chemistries on Antibody Performance for Reverse Phase Protein Arrays |
| Q50420907 | Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer |
| Q35785226 | Impact of proteomics on bladder cancer research. |
| Q47146356 | Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. |
| Q42710867 | Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification |
| Q28250373 | Laser capture microdissection technology |
| Q60673340 | Laser-capture microdissection |
| Q38010665 | Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations |
| Q36406525 | Multiplexed Quantitation of Protein Expression and Phosphorylation Based on Functionalized Soluble Nanopolymers |
| Q33217470 | Novel proteomic approaches for tissue analysis |
| Q33416583 | Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures |
| Q54979241 | Personalization of prostate cancer therapy through phosphoproteomics. |
| Q36219744 | Phosphoproteomics for oncology discovery and treatment |
| Q21184157 | Phosphoproteomics: new insights into cellular signaling |
| Q83100508 | Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray |
| Q34361084 | Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samples |
| Q28249165 | Porous silicon protein microarray technology and ultra-/superhydrophobic states for improved bioanalytical readout |
| Q40044147 | Porous silicon surfaces: a candidate substrate for reverse protein arrays in cancer biomarker detection |
| Q36897569 | Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays |
| Q54239638 | Protein expression profiling during wallerian degeneration after rat sciatic nerve injury |
| Q37844152 | Protein microarrays and novel detection platforms |
| Q36168440 | Protein microarrays as a discovery tool for studying protein-protein interactions |
| Q34514797 | Proteomic Approaches to the Discovery of Cancer Biomarkers for Early Detection and Personalized Medicine |
| Q35917826 | Proteomic approaches in drug discovery and development. |
| Q28766969 | Proteomics and mass spectrometry for cancer biomarker discovery |
| Q33293341 | Proteomics in cancer. |
| Q33697764 | Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer |
| Q34500104 | RNAi-based validation of antibodies for reverse phase protein arrays |
| Q33395131 | RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays |
| Q34479359 | Recent advances of protein microarrays. |
| Q28384553 | Reverse phase protein microarrays advance to use in clinical trials |
| Q36950451 | Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. |
| Q33217467 | Role of oncoproteomics in the personalized management of cancer |
| Q36381224 | Role of proteomics in translational research in cervical cancer |
| Q53659324 | Serum microarrays for large scale screening of protein levels. |
| Q35809020 | Spatiotemporal expression profiling of proteins in rat sciatic nerve regeneration using reverse phase protein arrays |
| Q42540737 | Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots |
| Q37945786 | Targeted protein-omic methods are bridging the gap between proteomic and hypothesis-driven protein analysis approaches |
| Q34422523 | Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues |
| Q36472432 | Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays |
| Q38432539 | The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology |
| Q37038561 | Validation and quality control of protein microarray-based analytical methods |
| Q51347842 | Validation of Biomarker Proteins Using Reverse Capture Protein Microarrays |
| Q34354775 | Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer |
| Q38545364 | Variable slope normalization of reverse phase protein arrays |
| Q35035679 | Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer |
| Q33217474 | What can proteomic analyses contribute to understanding the molecular biology and clinical behavior of prostate cancer? |
Search more.